These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17191268)

  • 21. Quality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatology.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Aust N Z J Psychiatry; 2007 May; 41(5):442-9. PubMed ID: 17464737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.
    Gunduz-Bruce H; Oliver S; Gueorguieva R; Forselius-Bielen K; D'Souza DC; Zimolo Z; Tek C; Kaliora S; Ray S; Petrides G
    Schizophr Res; 2013 Feb; 143(2-3):344-7. PubMed ID: 23219861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study.
    Lin CC; Chiu HJ; Chen JY; Liou YJ; Wang YC; Chen TT; Bai YM
    J Clin Psychopharmacol; 2013 Apr; 33(2):211-4. PubMed ID: 23422395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].
    Bouhlel S; M'solly M; Benhawala S; Jones Y; El-Hechmi Z
    Encephale; 2013 Feb; 39(1):6-12. PubMed ID: 23095582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China.
    Hou CL; Ma XR; Zang Y; Jia FJ; Lin YQ; Chiu HF; Ungvari GS; Ng CH; Zhong BL; Cao XL; Li Y; Cai MY; Xiang YT
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):36-42. PubMed ID: 26521927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Leponex, 10 years after -- a clinical review].
    Llorca PM; Pere JJ
    Encephale; 2004; 30(5):474-91. PubMed ID: 15627052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study.
    Genç Y; Taner E; Candansayar S
    Adv Ther; 2007; 24(1):1-13. PubMed ID: 17526456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.
    Kumra S; Kranzler H; Gerbino-Rosen G; Kester HM; De Thomas C; Kafantaris V; Correll CU; Kane JM
    Biol Psychiatry; 2008 Mar; 63(5):524-9. PubMed ID: 17651705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
    Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
    Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
    Meltzer HY; Alphs L; Green AI; Altamura AC; Anand R; Bertoldi A; Bourgeois M; Chouinard G; Islam MZ; Kane J; Krishnan R; Lindenmayer JP; Potkin S;
    Arch Gen Psychiatry; 2003 Jan; 60(1):82-91. PubMed ID: 12511175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. History of suicidal behavior and clozapine prescribing among people with schizophrenia in China: a cohort study.
    Yin Y; Lin C; Wei L; Tong J; Huang J; Tian B; Tan S; Wang Z; Yang F; Tong Y; Chen S; Hong LE; Tan Y
    BMC Psychiatry; 2024 Jun; 24(1):440. PubMed ID: 38867174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.
    Umbricht DS; Wirshing WC; Wirshing DA; McMeniman M; Schooler NR; Marder SR; Kane JM
    J Clin Psychiatry; 2002 May; 63(5):420-4. PubMed ID: 12019667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial.
    Takeuchi H; Lee J; Fervaha G; Foussias G; Agid O; Remington G
    J Clin Psychiatry; 2017 Feb; 78(2):223-228. PubMed ID: 28234436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.